Genexine, Inc.

The Green Cross Corporation

Postech Foundation

Daewoong Pharmaceutical Co., Ltd.

Dong-a Pharmaceutical Co., Ltd

Se Hwan Yang

Donghoon Choi

Hye Seong Lim

Young Chul Sung

Min Woo Kim

Won Bae Kim

Sung Hee Lee

Man Ki Song

Seung Kew Yoon

Chang Geun Lee

Mi Sun Byun

Sang-In Yang

Jung-Won Woo

Sang In Yang

Chae Young Kim

Doo Hong Park

Eun Ju Shin

Young Chul 101-601 Hyundai Edong Hometown Sung

Kyu-Heum 312-1303 Cheongmyeong Dongshin Apt Na

Sung Hee 101-306 Nakseongdae Hyundai Apt Lee

Won Bae 1801 Daelim Acrovill Apt Kim

Jong Moon Son

Byung Moon Kim

Se Jin Im

Su Hyung Park

The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.

Method of treating anemia using long-acting EPO formulation

The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.

Modified interleukin-7 protein

The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs. Accordingly, the fusion polypeptide of the present invention can be effectively applied to pharmaceutical drugs.

Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof

Growing community of inventors

Seoul, South Korea

Se Hwan Yang